Previous studies have demonstrated that Kras mutation-mediated abnormal glucose metabolism would lead to an aberrant cell proliferation in human pancreatic ductal adenocarcinoma (PDAC) cells. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.